Biotech developing systemically administered RNAi therapies for neurological diseases.
| Date | Round | Amount |
|---|---|---|
| Feb 2026 | Series A Dublin-based Aerska closes a 39 million dollar Series A led by EQT Dementia Fund and Age1 with Iaso Ventures, bringing total funding to 60 million. | $39M |
| Oct 2025 | Seed Aerska came out of stealth with a $21 million seed co-led by Age1, Backed VC and Speedinvest for RNAi therapies against Alzheimer's and Parkinson's. | $21M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.